Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Shares Outstanding (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Shares Outstanding for 6 consecutive years, with $24.5 million as the latest value for Q2 2023.

  • On a quarterly basis, Shares Outstanding rose 16.67% to $24.5 million in Q2 2023 year-over-year; TTM through Jun 2023 was $24.5 million, a 16.67% increase, with the full-year FY2022 number at $24.4 million, up 16.94% from a year prior.
  • Shares Outstanding was $24.5 million for Q2 2023 at Whitehawk Therapeutics, roughly flat from $24.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $47.1 million in Q3 2020 to a low of $2542.0 in Q2 2020.
  • A 5-year average of $23.6 million and a median of $24.4 million in 2022 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: plummeted 100.0% in 2020, then soared 2844995.37% in 2021.
  • Whitehawk Therapeutics' Shares Outstanding stood at $734000.0 in 2019, then plummeted by 99.9% to $734.0 in 2020, then soared by 2846630.25% to $20.9 million in 2021, then grew by 16.94% to $24.4 million in 2022, then increased by 0.35% to $24.5 million in 2023.
  • Per Business Quant, the three most recent readings for WHWK's Shares Outstanding are $24.5 million (Q2 2023), $24.4 million (Q1 2023), and $24.4 million (Q4 2022).